GlassScriptPhysician profile
Matthew J Aresery
NPI 1447205281
$5,296.18
in general payments reported to CMS, 2019-2025
23 companies · $955 in 2025
The $955 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,053 · 2020: $646 · 2021: $572 · 2022: $1,002 · 2023: $468 · 2024: $599 · 2025: $955.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,902 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,902.09 |
| Education | $120.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,157.35 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $1,072.52 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Regeneron Healthcare Solutions, INC. | $419.75 | 2019-2025 | Dupixent |
| Genzyme Corporation | $362.54 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $315.33 | 2021-2025 | Cuvitru, Hyqvia, Eohilia |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $314.72 | 2019-2021 | |
| Amarin Pharma, INC. | $255.89 | 2019 | |
| Genentech USA, INC. | $250.82 | 2019-2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $141.90 | 2021-2025 | |
| Actelion Pharmaceuticals US, INC. | $124.80 | 2020 | |
| Boston Scientific Corporation | $122.56 | 2019 | |
| Biocryst US Sales Co., LLC | $120.71 | 2022 | |
| Therapeuticsmd, INC. | $120.54 | 2019 | |
| Regeneron Pharmaceuticals, INC. | $107.41 | 2022 | |
| Amgen INC. | $107.29 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $84.99 | 2024 | |
| Globus Medical, INC. | $48.74 | 2025 | Senza |
| Alk-Abello, INC | $44.74 | 2025 | Grastek, Odactra, Ragwitek |
| Optinose US, INC. | $36.93 | 2022-2025 | |
| Coastal Medical Technologies LLC | $27.30 | 2025 | |
| Merck Sharp & Dohme LLC | $22.10 | 2023 | |
| Hikma Pharmaceuticals USA | $19.25 | 2023 | Ryaltris |
| Novo Nordisk INC | $18.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Aresery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.